SCL Science Inc. (KOSDAQ: 246960)

Market Cap	65.55B
Revenue (ttm)	3.06B
Net Income (ttm)	-1.83B
Shares Out	7.28M
EPS (ttm)	-265.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,177
Open	9,180.00
Previous Close	9,180.00
Day's Range	9,040.00 - 9,320.00
52-Week Range	7,200.00 - 11,850.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About SCL Science

SCL Science Inc., engages in the development and sale of medical sealant products in South Korea. The company’s products include InnoSEAL, an externally applied hemostatic agent; InnoSEAL Plus, an absorbable hemostatic pad; EndoSil, an absorbable hemostatic agent used for the gastrointestinal oozing bleeding; GellySil, a biomaterial and the proprietary material product. It also provides Film-type surgical sealant to complete sealing of anastomosis site; STOP needle, a self-sealing needle for general and ophthalmic use; wound dressing used for c...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Employees: 44
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2023, SCL Science's revenue was 1.32 billion, an increase of 257.54% compared to the previous year's 369.78 million. Losses were -5.03 billion, -15.83% less than in 2022.